Bicara Therapeutics Inc. Common Stock (BCAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has a cash flow conversion efficiency ratio of -0.073x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.51 Million) by net assets ($513.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BCAX net asset quality index to measure how much of total assets are equity-financed.
Bicara Therapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Bicara Therapeutics Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
Bicara Therapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China National Building Material Company Limited
F:D1Y
|
0.022x |
|
Minda Corporation Limited
NSE:MINDACORP
|
0.126x |
|
Hycroft Mining Holding Corporation
NASDAQ:HYMC
|
-0.140x |
|
Guangdong Alpha Animation and Culture Co Ltd
SHE:002292
|
-0.014x |
|
Kumho Petro Chemical
KO:011780
|
0.027x |
|
Gansu Qilianshan Cement Group Co Ltd
SHG:600720
|
0.016x |
|
Punjab & Sind Bank
NSE:PSB
|
-0.594x |
|
Stolt-Nielsen Limited
OL:SNI
|
0.060x |
Annual Cash Flow Conversion Efficiency for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Bicara Therapeutics Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $401.45 Million | $-106.83 Million | -0.266x | -75.11% |
| 2024-12-31 | $491.88 Million | $-74.75 Million | -0.152x | +27.22% |
| 2023-12-31 | $218.51 Million | $-45.63 Million | -0.209x | -111.25% |
| 2022-12-31 | $-17.28 Million | $-32.08 Million | 1.856x | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more